Autoimmune Neurology Series
India’s only validated 7-marker MG panel – and what our national dataset of 388 cases reveals about the diagnostic information lost when clinicians test for only two antibodies.
ZX
ZeiniX Life Sciences | Autoimmune Neurology Diagnostics | India
Expert Perspective
Myasthenia Gravis (MG) is among the most treatable autoimmune neurological conditions – provided, that is, that the correct antibody profile is identified. Yet across Indian clinical practice, a troubling pattern persists: patients with MG are being evaluated with partial antibody panels, often limited to only two markers, while the full spectrum of clinically actionable serology goes untested. This is not a matter of nuance. It has measurable, quantifiable consequences for diagnosis, risk stratification, and treatment outcomes.
At ZeiniX, we have had the opportunity to examine this problem not merely as a theoretical concern but through a validated national dataset of 388 patients tested with a comprehensive 7-marker MG panel in the last 6 months (till March 2026). What that data reveals is unambiguous: partial testing misses the complete antibody picture in nearly three out of every four seropositive MG patients. This article presents those findings and explains why comprehensive MG antibody profiling is not a diagnostic luxury – it is the clinical standard.
Testing only two antibodies in a condition defined by its antibody diversity is not a diagnosis – it is a partial view of a disease that demands a complete one.
The ZeiniX 7-Marker MG Panel: Complete Autoimmune Profiling
MG is a heterogeneous condition. The clinical phenotype, disease severity, risk of thymoma, likelihood of generalisation, and response to specific therapies all vary significantly depending on which antibody – or combination of antibodies – is driving the disease. A diagnostic framework that captures only a portion of this antigenic landscape cannot adequately inform clinical decisions.
The ZeiniX 7-marker MG panel was developed precisely to address this gap. It covers the full spectrum of currently characterised pathogenic and clinically significant MG-associated antibodies:
AChR
Acetylcholine Receptor
Classic MG; most prevalent globally
MUSK
Muscle-Specific Kinase
Seronegative for AChR; distinct phenotype
Agrin
Neuromuscular junction
Double-seronegative MG
LRP4
Low-density lipoprotein receptor-related protein 4
NMJ clustering; seronegative MG
Striational
Sarcomeric antigens
Thymoma risk marker
Titin
Sarcomeric structural protein
Severe MG; thymoma association
Ryanodine
Ryanodine receptor
Myocardial risk; severe phenotype
388
Indian patients in our national
comprehensive MG panel dataset
78.6%
Overall seropositivity rate using the full
7-marker panel
74.4%
Of seropositive patients whose full
antibody profile was missed by
Agrin/LRP4 alone
What the National Dataset Actually Shows
The evidence at the centre of this discussion comes from a real-world scenario: a tertiary care hospital in India whose routine practice was to test MG patients for only two antibodies – Agrin and LRP4. Working from that hospital’s dataset of 39 patients alongside our national cohort of 388 comprehensively tested cases, a clear and concerning picture emerges.
Seropositivity: A Misleadingly Optimistic Number
The hospital’s partial Agrin/LRP4 panel returned a positivity rate of 66.7% – a figure that, on its surface, appears reasonable. But this number conceals more than it reveals. The hospital was largely referring difficult or double-seronegative (for AChR & MuSK) cases, meaning the panel was functioning as a last resort rather than a systematic screen. More critically, what the 66.7% positivity rate actually measured was only Agrin and LRP4 reactivity. The full antibody burden – co-positivity for Striational, Titin, Ryanodine, AChR, or MuSK – remained entirely unknown for every patient in that cohort.
Against the national dataset, the full picture is starkly different:
Critical finding
In 227 of 305 seropositive patients – 74.4% – the extended panel provided additional or alternative diagnostic information that testing only Agrin and LRP4 would have entirely missed. This is not marginal under-detection. It is a systematic failure of diagnostic scope.
The implication is direct: any clinical decision made on the basis of an Agrin/LRP4-only panel is a decision made without knowledge of the full serological picture in nearly three out of four patients who have autoimmune MG.
The Partial Panel Problem: What Gets Missed, and Why It Matters
The three antibodies most consistently absent from partial commercial MG panels – Striational, Titin, and Ryanodine – are not ancillary markers. In the context of MG, they carry information that is directly actionable in clinical management.
Striational, Titin, and Ryanodine: The Markers That Determine Prognosis
These three antibodies occupy a distinct clinical role in MG – they are not simply additional confirmation of the diagnosis, but markers of disease severity and systemic risk. Their presence in a patient’s serology is a signal that demands a different level of clinical attention and a different management pathway.
Anti-Striational antibodies are strongly associated with thymoma. In any patient with MG-related Striational positivity, thymoma screening with cross-sectional chest imaging is not optional – it is urgent. Thymoma is a potentially malignant mediastinal tumour that is both treatable if caught early and potentially fatal if missed. A panel that does not test for Striational antibodies is a panel that may allow a thymoma to go undetected.
Anti-Titin antibodies similarly flag a high-risk MG phenotype. Titin positivity is associated with thymoma, severe generalised disease, and a clinical course that is often more aggressive and more likely to require escalated immunotherapy. It is also observed in late-onset MG, where the clinical phenotype can be atypical and thymoma screening is often not initially considered.
Anti-Ryanodine antibodies carry a further dimension of risk: myocardial involvement. Ryanodine receptor antibodies are associated with cardiac muscle dysfunction in MG – a complication that, if not identified and monitored, can lead to serious and unexpected cardiac events. Identifying Ryanodine positivity prompts cardiac surveillance that an incomplete panel will never initiate.
The 70 Truly Missed Diagnoses
Perhaps the most sobering data point in our national dataset is this: 70 of the 305 seropositive MG patients – 22.9% – had no Agrin or LRP4 positivity at all. Their MG serology resided entirely in other markers: Striational, Ryanodine, Titin, MuSK, or AChR. In a clinical setting running only an Agrin/LRP4 panel, these 70 patients would have returned a negative result. They would not have received a diagnosis. They would have continued along a diagnostic odyssey whose conclusion – delayed treatment, progressive disease, potential thymoma growth, potential cardiac risk – was entirely preventable.
Multi-Antibody Positivity: Risk Stratification the Partial Panel Cannot Provide
Beyond the binary question of seropositive or seronegative lies a more nuanced and clinically important dimension: co-antibody burden. Our data demonstrates that a substantial proportion of MG patients – 157 of 305 seropositive cases – are positive for Agrin or LRP4 in combination with one or more additional antibodies. This co-positivity is not incidental.
Multi-antibody positive MG patients tend to have more severe disease, greater treatment resistance, and a need for combination immunotherapy. Without the extended panel, this risk cannot even be quantified.
In clinical practice, the difference between a patient who is Agrin-positive alone and one who is Agrin-positive with concurrent Titin and Striational antibodies is the difference between a routine treatment pathway and one that demands immediate thymoma workup, consideration of aggressive immunotherapy, and close long-term monitoring. That distinction is invisible without comprehensive testing.
Marker Distribution from Our National Dataset
Agrin/LRP4 + others
51.5%
Agrin/LRP4 only
25.6%
Other markers only
22.9%
Distribution among 305 seropositive cases from the ZeiniX national MG dataset (n=388 total). Percentages represent share of seropositive patients.
The Economics of Partial Testing: False Savings, Real Costs
The argument most often offered in defence of partial panels is cost. A two-marker panel is cheaper than a seven-marker panel, and in resource-limited environments this appears a reasonable trade-off. This reasoning is flawed, and the data makes clear why.
Sequential re-testing costs
A partial panel that returns inconclusive or incomplete results invariably triggers additional testing. Multiple sample collections, repeat visits, and staged reporting accumulate a total cost that exceeds comprehensive upfront panel testing – while also introducing delay.
Clinical escalation costs
A missed Striational or Titin result that delays thymoma detection, or a missed Ryanodine result that allows cardiac disease to progress, can lead to ICU admissions, ventilator support, plasma exchange, and prolonged hospitalisation. The cost of a single day in intensive care significantly exceeds the cost of the extended panel.
The diagnostic odyssey cost
Patients who remain seronegative on a partial panel continue to circulate through the healthcare system – repeat neurology consultations, additional EMG and imaging, empirical treatment trials, suboptimal outcomes. The extended panel, by delivering single-step diagnostic clarity, ends this cycle.
The cost comparison is not between a cheap test and an expensive one. It is between comprehensive first-step testing and the cumulative downstream cost of incomplete information – a cost borne disproportionately by the patient.
What Clinicians and Patients Should Ask
When an MG antibody report is returned, the questions should extend beyond interpreting the result. They should begin with the test itself.
When an MG antibody report is returned, the questions should extend beyond interpreting the result. They should begin with the test itself.
Questions Every Ordering Clinician Should Ask
- Does the panel include AChR and MuSK - the two most prevalent MG antibodies globally - in addition to Agrin and LRP4?
- Does it include Striational and Titin antibodies, which are the primary serological indicators of thymoma risk and severe disease phenotype in MG?
- Does it include Ryanodine antibodies, which signal the possibility of myocardial involvement and the need for cardiac monitoring?
- Is the laboratory running a validated assay with confirmed positive controls for each marker - not sourcing reagent kits for a subset of antigens without the capacity to verify assay performance?
- Does the laboratory have focused expertise in autoimmune neurology, or is MG antibody testing one of hundreds of general immunology tests run without specialised oversight?
A panel that cannot answer yes to each of these questions is not a comprehensive MG screen. It is a partial view being presented as a complete one – and in autoimmune MG, partial views cost patients their diagnosis.
Conclusion: Partial Testing in MG Is Not Acceptable Practice
The data is unambiguous. In our national dataset of 388 Indian patients tested with a comprehensive 7-marker MG panel, 74.4% of seropositive patients carried antibody information that an Agrin/LRP4-only panel would have entirely failed to detect. Twenty-three percent had no Agrin or LRP4 positivity whatsoever – they would have been falsely seronegative. Over half carried additional antibodies that materially changed their risk profile, their thymoma screening urgency, and their treatment requirements.
Myasthenia Gravis is a treatable condition. The trajectory of this disease – whether a patient is identified early, thymoma screening is initiated promptly, cardiac risk is recognised and monitored, and immunotherapy is appropriately escalated – depends fundamentally on the completeness of their antibody profile. Partial testing does not provide that profile. It provides a fragment, and clinical decisions made on a fragment are decisions made in the dark.
ZeiniX offers the only validated 7-marker MG panel in India – validated against confirmed positive controls, underpinned by a national dataset that no other laboratory in India can match, and designed to give every MG patient the serological clarity that their diagnosis and treatment demands. The additional cost of comprehensive testing over partial testing is negligible. The cost of the diagnostic information it provides is not.
References
- ZeiniX Life Sciences is India’s dedicated autoimmune neurology diagnostics service provider.
- The 7-marker MG panel – comprising AChR, MuSK, Agrin, LRP4, Striational, Titin, and Ryanodine antibodies – is offered exclusively by ZeiniX, validated against confirmed Indian patient positive controls.
- National dataset includes 388 patients meeting criteria for comprehensive or extended 5/7-marker panel testing. For clinical queries and referrals, contact your ZeiniX representative.
- Data on file; supporting analysis available on request.